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Abstract
Mitochondrial dysfunction occurs in many neurodegenerative diseases. The a-ketoglutarate dehydrogenase complex (KGDHC) catalyzes
a key and arguably rate-limiting step of the tricarboxylic acid cycle (TCA). A reduction in the activity of the KGDHC occurs in brains and
cells of patients with many of these disorders and may underlie the abnormal mitochondrial function. Abnormalities in calcium homeostasis
also occur in fibroblasts from Alzheimer’s disease (AD) patients and in cells bearing mutations that lead to AD. Thus, the present studies test
whether the reduction of KGDHC activity can lead to the alterations in mitochondrial function and calcium homeostasis. a-Keto-h-methyl-n-
valeric acid (KMV) inhibits KGDHC activity in living N2a cells in a dose- and time-dependent manner. Surprisingly, concentration of KMV
that inhibit in situ KGDHC by 80% does not alter the mitochondrial membrane potential (MMP). However, similar concentrations of KMV
induce the release of cytochrome c from mitochondria into the cytosol, reduce basal [Ca2 +]i by 23% (P< 0.005), and diminish the bradykinin
(BK)-induced calcium release from the endoplasmic reticulum (ER) by 46% (P < 0.005). This result suggests that diminished KGDHC
activities do not lead to the Ca2 + abnormalities in fibroblasts from AD patients or cells bearing PS-1 mutations. The increased release of
cytochrome c with diminished KGDHC activities will be expected to activate other pathways including cell death cascades. Reductions in
this key mitochondrial enzyme will likely make the cells more vulnerable to metabolic insults that promote cell death.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Considerable evidence implicates mitochondrial dysfunc-
tion in several neurodegenerative diseases [1,2]. The a-
ketoglutarate dehydrogenase complex (KGDHC) is a mito-
chondrial enzyme complex that oxidatively decarboxylates
a-ketoglutarate to succinyl-CoA in the tricarboxylic acid
cycle (TCA). Diminished KGDHC activities (39–83%)
occur in Alzheimer’s disease (AD) in both histopathologi-
cally affected and histopathologically unaffected areas of
brain. This finding has been confirmed in four independent
laboratories [3–6], and there are no contravening reports.
KGDHC activity is reduced in fibroblasts from AD patients
[7]. KGDHC activity is also reduced in other neurodegener-
ative diseases, including Parkinson’s disease [8–11], Wer-
nicke–Korsakoff syndrome [12], spinocerebellar disorders
[13] and progressive supranuclear palsy [14,15]. Thus,
diminished KGDHC activity may underlie the mitochon-
drial abnormality in numerous disorders.
Another irregularity that occurs in cells from AD patients
is abnormal calcium homeostasis [16,17]. Bombesin-
induced Ca2 + release from the endoplasmic reticulum
(ER), which is inositol trisphosphate-mediated, is greatly
enhanced in AD fibroblasts [16,18,19]. Furthermore, bra-
dykinin (BK), another activator of phospholipase C, elicits
similar enhancement of Ca2 + signaling in AD fibroblasts
[16,18,19]. Whether this change is related to the reduction
in KGDHC activities that is discussed in the first paragraph
is unknown. Thus, the goal of the current study was to
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determine if reduced KGDHC activities could lead to the
alterations in calcium homeostasis.
The mitochondrial membrane potential (MMP) provides
a sensitive measure of mitochondrial function. The MMP is
synonymous with the electrical membrane potential that
modulates Ca2 + regulation [20–22], and production of
reactive oxygen species [23,24]. The proton electrochemical
gradient potential, which controls ATP synthesis and respi-
ration, is the sum of the MMP and the proton gradient. Since
the pH component is generally small, MMP reflects the
functional status of mitochondria [25,26]. Accurate assess-
ment of the MMP within living cells under physiological
conditions is essential to our understanding of the role of
mitochondria in altered cell function. The experiments in
this paper use a unique method that complements inves-
tigations that estimate MMP of individual mitochondrion
[27–29] and those that assess MMP by examining global
fluorescence from cells [30–32]. The method utilizes tetra-
methylrhodamine methyl ester (TMRM) at concentrations
and exposure times that minimize phototoxicity and assure
that changes in intensity reflect a change in the MMP [33].
In addition to their role in maintaining cellular ATP and
regulating cellular calcium, mitochondria regulate apoptotic
cascades in the cells by release of cytochrome c. The
relationship between the release of cytochrome c and
MMP is controversial. Cytochrome c is located on the inner
membrane of mitochondria and links complex III with
cytochrome c oxidase. Some reports suggest that the release
of cytochrome c from mitochondria depends on the reduction
of MMP [34–38] and/or induction of mitochondrial perme-
ability transition (MPT) [39,40]. On the other hand, others
suggest that the release of cytochrome c occurs without
depolarization of MMP [30,41–44] or the MPT [45].
ER and mitochondria are intimately connected. Mito-
chondrial Ca2 + not only regulates mitochondrial metabo-
lism and transient MMP but also regulates cytosolic free
Ca2 + concentration ([Ca2 +]i) and the ER Ca
2 + store [46–
48]. Mitochondria regulate [Ca2 +]i through the local regu-
lation of IP3-sensitive channels in the ER [48,49]. These
microdomains allow rapid uptake of Ca2 + by mitochondria
prior to release in cytosol. Mitochondria take up the Ca2 +
when [Ca2 +]i is above the set point and release it back into
the cytosol when the [Ca2 +]i is below this set value [46–
48]. Mitochondria also regulate [Ca2 +]i and ER Ca
2 + stores
by altering the level of ATP, which may affect the activity of
ion pumps responsible for removing Ca2 + from the cytosol
either to the extracellular space or into the ER [50]. There-
fore, altered mitochondrial bioenergetics will change
[Ca2 +]i and ER Ca
2 + stores. Increases in Ca2 + concentra-
tions in response to stimulus are reduced in both cytosol and
mitochondria under conditions that lead to apoptosis
[51,52].
The goal of the current studies was to test whether
reduced KGDHC activities could lead to changes in mito-
chondrial function (including measures of bioenergetics and
release of signaling molecules) and to alterations in calcium
that occur in fibroblasts from AD patients. KGDHC was
inhibited with a-keto-h-methyl-n-valeric acid (KMV), a
structural analogue of a-ketoglutarate, that is a relatively
specific competitive inhibitor of KGDHC [54]. For exam-
ple, 20-mM KMV inhibits isolated rat brain KGDHC [54] or
KGDHC in isolated mitochondria [54] by 99%. On the other
hand, KMVonly slightly inhibits (12% or less) [53] or does
not inhibit [55] the pyruvate dehydrogenase complex, a very
similar enzyme. Thus, KMV, which effectively and rela-
tively specifically inhibits KGDHC activity, was utilized to
test the relation of KGDHC inhibition and MMP to the
release of cytochrome c and calcium homeostasis in N2a
neuroblastoma cells.
2. Materials and methods
The supplies were obtained from the indicated companies:
all of the enzymes, substrates and KMV (Sigma Chemical
Co., St. Louis, MO), fura-2-acetoxymethyl ester (fura-2AM)
and TMRM (Molecular Probes, Eugene, OR), cell culture
reagents (GIBCO, Grand Island, NY), mouse monoclonal
anti-cytochrome c antibody (BD PharMingen, San Diego,
CA), horseradish peroxidase (HRP)-conjugated anti-mouse
antibodies (Jackson Immuno-Research Lab., West Grove,
PA), and anti-mouse tubulin mAb (Promega, Madison,
WI).
2.1. Cultured cells
N2a neuroblastoma cells were purchased from the Amer-
ican Type Culture Collection (Manassas, VA). The cells
were maintained at 37 jC in a humidified incubator with 5%
CO2 and 95% air in Dulbecco’s modified Eagle’s medium
(DMEM) containing 10% fetal bovine serum (FBS). Cells
were subcultured twice a week.
2.2. In situ KGDHC activity
The in situ activity of KGDHC was measured in intact
living cells by the formation of a dark blue formazan
product, which was produced from an electron transfer from
NADH to nitroblue tetrazolium (NBT) [56]. Since other
cellular dehydrogenases (e.g. pyruvate dehydrogenase com-
plex or glutamate dehydrogenase) also utilize NAD+, the
specificity of the in situ staining for KGDHCwas determined
by subtracting the background in the absence of substrate a-
KG and Co-A. N2a cells were seeded at a density of 105 cell/
well in 24-well plates pre-coated with poly-D-lysine (5 Ag/
ml) 2 days before the experiments. On the day of experiment,
the medium was aspirated, and the cells were washed with
balanced salt solution (BSS in mM: NaCl 140, KCl 5, CaCl2
2.5, MgCl2 1, glucose 5, HEPES 10, pH 7.4 at 371 jC). The
cells were then incubated with or without KMV in BSS for
the indicated times. At the end of treatment the medium was
changed to assay media as described previously [56] with or
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without KMV. Since KMV is a reversible inhibitor for
KGDHC, it was also included during the assay. After
incubation, the treatment medium was aspirated, and the
cells were washed with Ca2 +/Mg2 +-free Hank’s Balanced
Salt Solution (HBSS). The dark blue formazan product was
solubilized with SDS (10%) in 0.01 N HCl overnight in the
CO2 incubator (37 jC). The absorbance was read at 570 nm
with Spectra Max 250 model plate reader (Molecular Devi-
ces; Sunnyvale, CA).
2.3. Mitochondrial membrane potential
Accurate assessment of the MMP within living cells
under physiological conditions (37 jC) is essential to
understand the role of mitochondria in altered cell function
following inhibition of mitochondrial enzymes. Our recently
published method provides a quantitative estimate of the
MMP of populations of mitochondria-like particles (MLP)
in a single cell under physiological condition. The method
allows us to study the heterogeneity of the MMP of
mitochondria (MLP) within individual cells and between
cells. Changes in the MMP of MLP as small as 5% in either
direction are detectable. This method combines conven-
tional fluorescence microscopy and 3-D deconvolution by
exhaustive photon reassignment (EPR) (Scanalytics, Fair-
fax, VA). We have optimized the dye concentrations and
exposure times for the fluorescent signal of TMRM [33].
The ability to determine small changes in the MMP in
depolarization or hyperpolarization suggests that self-
quenching and matrix aggregation of the dye were not a
problem. The stability of the MMP in controls during the
time of incubations indicates phototoxicity is not a problem.
A brief description of the method follows. N2a cells were
seeded on poly-D-lysine pre-coated Delta T 3.5-cm dishes at
4 104/dish (Bioptechs; Butler, PA) overnight. On the day
of experiment, cells were loaded with TMRM (50 nM) in a
BSS for 40 min at 37 jC. Stacks of fluorescence images were
obtained with excitation at 540 nm and emission at 590 nm
with a Delta Scan System from Photon Technology Interna-
tional (PTI, Lawrenceville, NJ; xenon light source, 75 W)
equipped with a 12-bit digital cooled CCD Quantix camera
(Photometrics, Tucson, AZ). Stacks of fluorescence images
with 700-ms light exposure each, 0.25 Am per step, were
taken at different time intervals. Point spread functions (PSF)
to correct for light from other planes by EPR (Scanalytics)
were acquired under the same conditions as the samples.
The images were analyzed by a combination of Meta-
morph and Microsoft Excel. This method utilizes the ratio of
the TMRM signal from the mitochondria to that of the
cytosol. The cytosolic values are taken to be equal to that of
the nucleus. The mitochondrial values are taken to be the
values that exceed a threshold of the nuclear signal plus 3
standard deviations. An MLP was defined as a group of two
or more adjacent pixels that exceeded the threshold. A
numerical estimate of the MMP was obtained by inserting
the ratio of mitochondrial fluorescence to that of the cytosol
in the Nernst equation. The average MMP of all MLP for
each cell (mean MMP) was calculated. An alternative way
of analyzing these data is to regard each pixel that exceeds
the threshold as an independent signal, calculate its potential
and sum of the potentials of all pixels for each cell.
2.4. Accumulation of cytochrome c in the cytosol
N2a cells were seeded at 6 106 cells per 10-cm dish 1
day before the experiment. On the day of experiment, the
medium was aspirated, and the cells were washed once with
phosphate-buffered saline (PBS). Cells were treated with or
without KMV (20 mM) in BSS for 80 min at 37 jC. After
treatment, the mitochondrial and cytosolic fractions were
isolated by modifications of published methods [57]. Cells
were washed with ice-cold PBS and then incubated in 0.3 ml
of lysis buffer (in mM: HEPES–KOH, 20, pH 7.5; MgCl2,
1.5; EDTA, 2; EGTA, 5; dithiothreitol, 0.1; phenylmethyl-
sulfonylfluoride, 0.1; sucrose 250) on ice for 30 min before
scraping. Cell lysates were homogenized in Eppendorf tubes
with 10 strokes of a motorized homogenizer, and then
centrifuged at 500 g for 10 min to remove unbroken cells
and nuclei. Supernatants were centrifuged at 10,000 g for
30 min. The pellets (i.e. mitochondrial fraction) were
resuspended in lysis buffer. The supernatants of the
10,000 g spin were further centrifuged at 100,000 g
(BECKMAN TLX ultracentrifuge) for 60 min to yield
cytosolic fractions.
Twenty micrograms (mitochondria) or 40 Ag (cytosol) of
protein was loaded to each lane of a 15% sodium dodecyl
sulfate-polyacrylamide gel (SDS-PAGE) electrophoresis.
Resolved proteins were electroblotted onto PVDF transfer
membranes (NEN; Boston, MA). The blots were incubated
with Tris-buffered saline-Tween (TBST; 0.1 M Tris buffer,
pH 7.4, 0.9% NaCl, 0.1% Tween 20) and 5% skim milk
containing anti-cytochrome c (1:500; BD PharMingen Tech)
or anti-tubulin (1:2000; Promega) monoclonal antibody
overnight. Blots were then incubated with horseradish per-
oxidase conjugated affinity goat anti-mouse IgG (1:5000;
Jackson) for 1 h. The bound immunoproteins were detected
by enhanced chemiluminescent assay (ECL, Amersham
Pharmarcia Biotech; Piscataway, NJ). Tubulin protein was
also determined in each blot to demonstrate that equal protein
was loaded on each lane. The immunoactivites of the bands
were semi-quantified by densitometeric scanner and ana-
lyzed by Quantity-One software (BioRad; Hercules, CA).
2.5. Measurement of [Ca2+]i
Fluorescence intracellular calcium images were moni-
tored according to our published method [18]. N2a cells
were loaded with 2 AM Fura-2 AM in BSS for 1 h at 37 jC
in a 5% CO2 incubator. Cells were rinsed twice and [Ca
2 +]i
was monitored on the stage of an inverted Olympus IX70
microscope at 37 jC with a Delta Scan System from PTI.
Excitation wavelengths were altered between 350 and 378
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nm (band pass 3 nm) and emission was monitored at 510 nm
with a Hamamatsu C2400SIT camera at 5-s intervals. Basal
[Ca2 +]i was measured for 1 min before the addition of BK
(10 nM). Then the BK-stimulated increase in [Ca2 +]i was
measured for 4 min. Each value was the average of 32
images taken within 5 s. Standard images of Fura 2
solutions with minimum and maximum [Ca2 +]i were taken
at the end of each day’s experiment to calculate the intra-
cellular calcium concentrations.
2.6. Statistical analysis
All data were expressed as meanF S.E. For single
variable comparisons, Student’s t test was used. For multiple
variable comparisons, data were analyzed by one-way
analysis of variance (ANOVA) followed by a Student–
Newman–Keul’s test.
3. Results
3.1. KMV inhibited in situ KGDHC activity
To determine the degree of inhibition by KMV, in situ
KGDHC activity in living N2a cells was assessed with a
histochemical assay [56]. N2a cells were treated with differ-
ent concentrations of KMV (0, 1, 10 and 20 mM) for the
indicated times (40, 60, 80, 120 and 240 min) (Fig. 1). KMV
inhibited KGDHC activities in a dose- and time-dependent
manner. Even a 4-h incubation with 1 mM KMV did not
reduce the in situ KGDHC activity. KMVat 10 and 20mM for
40 min inhibited KGDHC activities by 25F 5% and
46F 3%, respectively. KMV at 10 and 20 mM for 80 min
decreased KGDHC activity by 58F 5% and 80F 3.6%,
respectively. Longer incubation times (120 and 240 min) at
these higher KMV concentrations did not inhibit the enzyme
activity further. Thus, experiments on the release of cyto-
chrome c and calcium homeostasis were done with 20 mM
KMV for 80 min.
3.2. Effect of KMV on MMP in N2a cells
To determine whether diminished KGDHC activity
altered the bioenergetics of mitochondria, MMP were meas-
ured. This approach, which is described in Section 2, allows
us to assess heterogeneity of MMP for individual MLP
between cells. KMV did not alter several measures of the
MMP of cells. The mean MMP showed considerable
heterogeneity between cells under control conditions and
following treatment with KMV (Fig. 2, top). The mean
Fig. 1. KMV inhibited in situ KGDHC activity. N2a cells (105 cell/well)
were seeded into each well of a 24-well plate 1 day prior to the experiment.
On the day of experiment, the cells were washed twice with BSS, and then
pretreated with different concentrations of KMV (0, 1, 10 and 20 mM) for
the indicated times (0, 20, 40, 80 and 200 min) prior to the histochemical
KGDHC assay which was done in the presence of KMV for 40 min (see
Section 2). Thus, total treatment times with KMV were 40, 60, 80, 120 and
240 min. Each value represents the meanF S.E. of two separate experi-
ments done in three to four wells. Values with different letters vary
significantly from each other ( P< 0.05) by ANOVA followed by Student–
Newman–Keul’s test.
Fig. 2. Effects of KMV on distribution and temporal response of
mitochondrial membrane potentials (MMP). N2a cells were seeded on
delta T dishes 1 day before the experiment. On the day of experiment, N2a
cells were loaded with TMRM (50 nM) in BSS for 60 min at 37 jC, and
then the dishes were transferred to the stage of microscope and maintained
at 37 jC. The cells were treated with KMV (20 mM) or control buffer and
images were acquired at 0, 20, 40, 60 and 80 min. Top: Distribution of
mean MMP in cells treated with (n= 29) or without (n= 30) KMV for 80
min. Values on the vertical axis are the percent of the cell population with
the indicated mean MMP. Bottom: Mean cellular MMPF S.E. after KMV
treatment for different times. Values are presented as a percent of each cell’s
value at zero time.
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MMP range of the cells varied from  84 to  97 mV.
KMV did not alter distribution of the MMP of cells. The
average MMP of all MLP for each cell (mean MMP) was
not altered by KMV at any incubation time. If each cell’s
mean MMP was expressed as a percent of its value at zero
time, KMV had no effect (Fig. 2, bottom).
Alternative analysis of the fluorescent signals from
TMRM in the same cells provides greater power to distin-
guish small metabolic perturbations [33]. A method for
detecting small differences is to calculate the MMP for each
pixel that exceeds the threshold and sum the values of MMP
for each cell. This approach did not reveal any differences
between the control and the KMV group at 20, 40, 60 and
80 min (analysis not shown).
3.3. KMV induced accumulation of cytochrome c in the
cytosol
To test whether partial reduction of KGDHC induces
cytochrome c release from mitochondria in N2a cells, cells
were treated without or with KMV (20 mM) for 80 min.
After treatment, the protein levels of cytochrome c in the
cytosolic and mitochondrial fractions were determined (Fig.
3). Tubulin protein levels in the same blot were used as a
controls to show equivalent loading of protein on lanes that
were compared for cytochrome c. Inhibition of KGDHC by
KMV for 80 min increased accumulation of cytochrome c in
the cytosol by 161% (Fig. 3).
3.4. Inhibition of KGDHC alters calcium homeostasis
To test whether a partial reduction of KGDHC affects
[Ca2 +]i and ER Ca
2 + stores, N2a cells were treated with 20
mM KMV for 80 min. [Ca2 +]i was monitored for 1 min, and
then the cells were stimulated with BK (10 nM). KMV
reduced basal [Ca2 +]i by 23% from 101.9F 4.1 to 78F 2
nM (P < 0.005; n = 117 vs. 157), and reduced the BK-
induced release of calcium from the ER Ca2 + store by
46% from 629F 26 to 347F 13 nM (P < 0.005; Fig. 4).
Thus, inhibition of KGDHC reduced resting [Ca2 +]i con-
centration as well as BK-sensitive Ca2 + pools.
4. Discussion
The present results demonstrate that a partial inhibition
of KGDHC activities in N2a cells by KMV produces no
detectable changes in the MMPs, but stimulates release of
 
Fig. 3. KMV induced the accumulation of cytochrome c in the cytosol. The
N2a cells were treated with KMV (20 mM) or control buffer for 80 min.
The mitochondrial and cytosolic fractions were obtained according to the
procedures described in Section 2. Cytochrome c protein levels in
mitochondrial (20 Ag) and cytosolic (40 Ag) fractions were determined by
immunoblotting. Tubulin protein levels in the same blot were determined as
a control to assure that the levels of protein loading level on each lane were
coordinated. The bound immunoproteins were detected by ECL assay. The
top panel represents a typical immunoblot of cytochrome c in mitochondrial
(mit) and cytosolic fractions (cyt) after the cells were treated either without
(controls; C) or with KMV (K) was shown. The bottom panel represents the
relative intensities of the bands after they were semiquantified with a
densitometeric scanner and analyzed by Quantity-One software. Values are
meansF S.E. from two separate experiments and three blots from each.




Fig. 4. KMV altered calcium homeostasis in N2a cells. N2a cells were
pretreated with KMV for 15 min prior to loading with 2 AM Fura 2AM in
the presence of or absence of KMV for 60 min. Controls were treated the
same but without addition of KMV. After loading, the medium was washed
twice, and exactly 3 min later the resting cytosolic free calcium
concentration was monitored for 1 min at 5-s intervals. The top panel
shows the temporal response of [Ca2 +]i at resting level and after BK
stimulation. The arrow indicates the addition of BK (10 nM). The bottom
panel shows the basal level and the integration values of the [Ca2 +]i peak
after BK addition. Data are meansF S.E. Each value represents the
measurement of 117–157 cells in at least seven dishes measured on 2
separate days. * Denotes KMV differs significantly from the control
( P< 0.05) by Student–Newman–Keul’s test.
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cytochrome c from mitochondria into cytosol and produces
large changes in cellular Ca2 + homeostasis.
The present study showed that KMV inhibited KGDHC
in situ activity. KMV (20 mM) inhibited KGDHC by 80%
(Fig. 1). Although high concentrations of KMV (mM) are
required to reduce cellular KGDHC activities, the inhibition
is still rather specific. These results agree with previous
studies of purified KGDHC [53] and of isolated mitochon-
dria [54]. KMV at 10 and 20 mM effectively inhibits
partially purified KGDHC 78% and 99%, respectively
[53], as well as in disrupted rat brain mitochondria, but
does not inhibit PDHC [53,54].
Impairment of KGDHC was expected to reduce produc-
tion of NADH by the TCA cycle and thus diminish the
MMP, and the subsequent ability of the cell to synthesize
ATP. Measurement of KGDHC activity compared to other
TCA cycle enzymes suggest it may be rate-limiting in brain
slices [54]. This suggestion is supported by the studies of
isolated synaptosome showing that inhibition of KGDHC
correlates closely with impaired TCA cycle [58]. However,
KGDHC is not the rate-limiting enzyme for the TCA cycle
in fibroblasts [59]. Surprisingly, inhibition of 80% in situ
KGDHC activity does not alter the MMP in N2a cells.
The present study utilizes a new, novel and sensitive
technique to quantitatively analyze MMP in single living
cells at 37 jC [33]. This method bridges a gap between
detailed investigations of individual mitochondria and the
approaches that use global fluorescence to study mitochon-
dria. It can detect changes as small as 5%. The lack of
change in mean MMP is confirmed by lack of KMV-
induced change in the sum of MMP of all pixels of all
MLP for each cell. The results suggest that under these
experimental conditions, KGDHC activity is not limiting for
mitochondrial ability to maintain the MMP. One possible
mechanism that can maintain this potential is that the
glucose maintains the MMP by reversal of the ATP synthe-
tase. Normally, ATP synthetase uses the MMP to form ATP.
However, MMP can be maintained by the level of cytosolic
ATP produced by glycolysis when the respiration is blocked
[40,60]. Regardless of the mechanism for maintenance the
MMP, the results show that inhibition of KGDHC causes
profound changes in cellular functions.
The lack of change in MMP indicates that the release of
cytochrome c by KMV does not depend on a reduction in
MMP. The molecular mechanism responsible for the trans-
location of cytochrome c from mitochondria into cytosol is
unknown. Although cytochrome c release from the mito-
chondria has often been associated with diminished MMP
[61–64], cytochrome c release can also occur prior to the
loss of MMP or independent of the MMP [30,41,44,65] or
as a result of loss of the inner MMP [22,64,66]. A recent
study using single-cell analysis shows a transient loss of
MMP after cytochrome c release that is not apparent in
global cell analysis [42]. The present study measures MMP
on an individual cell basis, but transient alterations in the
MMP will not be apparent. Furthermore, the cytochrome c
release is assessed for the whole population of cells. Studies
in isolated liver mitochondria show that reduction of
KGDHC facilitates the mitochondrial permeability transi-
tion (MPT) and the effect is independent of the MMP [67].
Whether the MPT is coupled to MMP is controversial
[39,40,45]. Regardless of the mechanism, the present stud-
ies demonstrate that a large reduction in KGDHC activities
induces the release of cytochrome c from mitochondria into
cytosol without altering the MMP in N2a cells.
One of the goals of these studies was to determine
whether or not a reduction in KGDHC can lead to increased
ER Ca2 + store that accompanies AD-bearing mutations. ER
Ca2 + stores are linked to a variety of neurodegenerative
processes [68–71]. Bombesin-sensitive Ca2 + stores are
exaggerated in fibroblasts from AD patients as well as in
the neurons from PS1-transgenic mice [72]. In addition,
transfection of PS-1 in PC12 cells exaggerates Ca2 +
responses to carbachol or BK that induce Ca2 + release from
ER [73]. However, the present study shows that inhibition
of KGDHC activity reduces basal [Ca2 +]i and the ER Ca
2 +
stores, i.e. the opposite direction of those observed in AD
patients or in cells transfected with PS-1. Thus, the results
indicate that the reduction in KGDHC does not lead to the
calcium changes that accompany AD-causing mutations.
The link between reduced KGDHC, ER Ca2 + stores and
cytochrome c release is unknown, but free radical regulation
provides a plausible mechanistic link. Prominent thiol
groups in KGDHC subunits support cellular antioxidant
capacity through thioredoxin [74]. In thioredoxin-deficient
cells, cytochrome c is released even though the MMP is
maintained [75], i.e. a result similar to the current results.
One possible mechanism of cytochrome c release is via
opening of the mitochondrial permeability transition pore
(MPTP). The MPTP can also be regulated by disulfide
redox state [76–79]. The dihydrolipoate produced by
KGDHC is oxidized by thioredoxin [74], which results in
reduced form of thioredoxin. With less dihydrolipoate
produced following inhibition of KGDHC, less reduced
form of thioredoxin is available. In addition, the reduced
form, but not oxidized form, of thioredoxin is able to
mobilize both extra- and intracellular Ca2 + [80]. Thus,
diminished KGDHC will produce less reduced thioredoxin
and less Ca2 + release from ER. Therefore, the coupling of
KGDHC to thioredoxin provides a possible link between the
reduction of KGDHC and release of cytochrome c and
impairment of Ca2 + homeostasis.
ER and mitochondria are in close contact. Ca2 + cycles
communicate between mitochondria and ER Ca2 + [81,82].
Mitochondria locally regulate Ca2 + flux through IP3-sensi-
tive channels in the ER [49]. Ca2 + released from ER is
accumulated locally in microdomains and is taken up by
mitochondria prior to generation of change in global [Ca2 +]i
[48,83]. The supply of Ca2 + from mitochondria regulates
Ca2 + refilling in ER, and an alteration in the mitochondrial
Ca2 + interrupts ER Ca2 + homeostasis [82]. In addition,
three intramitochondrial TCA cycle enzymes (i.e. pyruvate,
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KGDHC and NAD+-dependent isocitrate dehydrogenase)
are stimulated by Ca2 + [84]. Activation of these enzymes
by Ca2 + can thus stimulate ATP synthesis [48]. KMV
inhibits KGDHC activity 80% which may decrease Ca2 +
uptake to the mitochondria and into the ER, and this will
lead to leakage of calcium from the cell and diminished
[Ca2 +]i.
In summary, the present results demonstrate that an 80%
reduction of KGDHC does not produce detectable changes
in the MMP but activates cytochrome c release from the
mitochondria. In addition, inhibition of KGDHC dramati-
cally reduces the cellular calcium stores that are exaggerated
in cells from Alzheimer patients or in cells bearing prese-
nilin mutations. This result suggest that reduction of
KGDHC is not the primary cause for the increase Ca2 +
response in AD. Inhibition of KGDHC with less reduced
form of thioredoxin may link the reduction in KGDHC to
ER Ca2 + homeostasis and cytochrome c release.
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